Search results

Narrow your search

Result types

Showing 111 - 120 of 186 for "Pharmaceuticals%20and%20life%20sciences" with applied filters

Firm

Dacheng Law Offices - China

Practice areas

Aviation and shipping, Banking and finance, Capital markets, Competition/antitrust, Construction, Corporate and M&A, Dispute resolution, Energy, Investment funds, Labour and employment, Private equity, Real estate, Regulatory, Restructuring and insolvency, Tax

Industry sectors

Energy, Industrials and manufacturing, Infrastructure, Mining

News & Analysis

Anand and Anand on-boards senior IP lawyer as TM partner

10 April 2024 by Anand and Anand

Anand and Anand on-boards senior IP lawyer as TM partner

News & Analysis

Division of an Application as a Tool to Enhance Private Value of a Patent

18 March 2024 by DPS Parmar (Special Counsel)

Division of an Application as a Tool to Enhance Private Value of a Patent

News & Analysis

Biological Material and Written Description Requirement under Patent Law

29 January 2024 by DPS Parmar (Special Counsel)

The three tenets of a patent grant are possession, disclosure, and claims of invention.

News & Analysis

Anatomy of Licensing Deals from China Regulatory Perspective

04 January 2024 by Aaron GU, Pengfei YOU, Duzhiyun ZHENG, Yuzhen ZHANG, Fengqi YU

Driven by the passion and belief, and fraught with various risks and challenges, the research and development of innovative drugs and medical devices is a journey that’s never easy.

News & Analysis

“Known Substance” Must be Disclosed Before the Date of Priority for Section 3(d) of Patents Act: Madras High Court

02 January 2024 by Manisha Singh (Partner) & Avi Garg (Partner)

Non-patentable inventions are always a bone of contention between the applicant and the patent office.

News & Analysis

Effects of the Draft Patent Rules, 2023 on Pharma Industry

30 November 2023 by Manisha Singh (Partner) & Harshini A. (Trainee Associate)

A couple of months back, the Ministry of Commerce and Industry published the Draft Patents (Amendment) Rules,2023, with various changes to the rules, regulations and fees, which welcomed suggestions and objections from the public.

News & Analysis

Relooking at the reach of Section 3(d) of the Indian Patents Act, 1970 after ‘Novozymes’ Case

30 October 2023 by LexOrbis - DPS Parmar

Section 3(d) of the Indian Patents Act, 1970 was never so controversial till the insertion of an amendment in 2005, which states that “the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance".

News & Analysis

Discovery vs Mere Discovery under Patent Law

11 September 2023 by LexOrbis - DPS Parmar

The term discovery is used in Section 3 (c) and Section 3 (d) of the Patents Act 1970, but it is not defined under the act and the Patent Rules 2003

News & Analysis

Does the Ongoing SAMR Merger Review Stop Enforcement of the Arbitral Awards?

15 August 2023 by AnJie Broad Law Firm : Hao ZHAN, Ying SONG, Wesley WANG

A recent ruling rendered by Beijing Higher People’s Court of China, on granting the enforcement of the arbitral awards, has attracted much attention and discussion of the competition law circle.